Ascelia Pharma AB (publ) (ACE.ST)
SEK 2.45
(-3.92%)
SEK 2.45
(-3.92%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 110.91 Million SEK | -22.86% |
| 2022 | 143.77 Million SEK | 11.31% |
| 2021 | 129.17 Million SEK | 38.51% |
| 2020 | 93.25 Million SEK | 154.23% |
| 2019 | 36.68 Million SEK | 5.95% |
| 2018 | 34.62 Million SEK | 40.09% |
| 2017 | 24.71 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 17.05 Million SEK | 42.64% |
| 2024 Q2 | 11.3 Million SEK | -33.56% |
| 2023 Q1 | 36.7 Million SEK | -24.99% |
| 2023 Q4 | 11.95 Million SEK | -44.04% |
| 2023 FY | 110.42 Million SEK | -23.19% |
| 2023 Q2 | 41.79 Million SEK | 13.85% |
| 2023 Q3 | 21.36 Million SEK | -48.88% |
| 2022 Q2 | 32.65 Million SEK | 0.25% |
| 2022 Q1 | 32.57 Million SEK | 7.19% |
| 2022 FY | 143.77 Million SEK | 11.31% |
| 2022 Q3 | 29.61 Million SEK | -9.29% |
| 2022 Q4 | 48.93 Million SEK | 65.23% |
| 2021 Q1 | 33.74 Million SEK | 21.77% |
| 2021 FY | 129.17 Million SEK | 38.51% |
| 2021 Q2 | 32.31 Million SEK | -4.23% |
| 2021 Q3 | 32.73 Million SEK | 1.31% |
| 2021 Q4 | 30.38 Million SEK | -7.18% |
| 2020 FY | 93.25 Million SEK | 154.23% |
| 2020 Q2 | 28.6 Million SEK | 38.46% |
| 2020 Q4 | 27.7 Million SEK | 70.07% |
| 2020 Q3 | 16.29 Million SEK | -43.04% |
| 2020 Q1 | 20.65 Million SEK | -9.96% |
| 2019 Q2 | 14.49 Million SEK | 23.77% |
| 2019 Q1 | 11.7 Million SEK | 61.64% |
| 2019 FY | 36.68 Million SEK | 5.95% |
| 2019 Q4 | 22.94 Million SEK | 65.26% |
| 2019 Q3 | 13.88 Million SEK | -4.22% |
| 2018 Q1 | 4.4 Million SEK | -52.78% |
| 2018 FY | 34.62 Million SEK | 40.09% |
| 2018 Q2 | 8.18 Million SEK | 85.53% |
| 2018 Q3 | 3.94 Million SEK | -51.75% |
| 2018 Q4 | 7.24 Million SEK | 83.53% |
| 2017 FY | 24.71 Million SEK | 0.0% |
| 2017 Q4 | 9.33 Million SEK | 54.05% |
| 2017 Q3 | 6.06 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Simris Alg AB (publ) | 38.64 Million SEK | -187.03% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 65.502% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 68.986% |
| Xintela AB (publ) | 57.31 Million SEK | -93.513% |
| Active Biotech AB (publ) | 44.8 Million SEK | -147.526% |
| Amniotics AB (publ) | 29.07 Million SEK | -281.515% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -656.937% |
| BioArctic AB (publ) | 89.62 Million SEK | -23.751% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 92.675% |
| Camurus AB (publ) | 1.05 Billion SEK | 89.533% |
| Cantargia AB (publ) | 290.01 Million SEK | 61.756% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -406.572% |
| CombiGene AB (publ) | 44.14 Million SEK | -151.254% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 22.431% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -291.558% |
| Genovis AB (publ.) | 88.19 Million SEK | -25.757% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 3.614% |
| Mendus AB (publ) | 129.13 Million SEK | 14.111% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -1426.059% |
| Intervacc AB (publ) | 79.78 Million SEK | -39.016% |
| Kancera AB (publ) | 63.07 Million SEK | -75.839% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -1909.676% |
| LIDDS AB (publ) | 27.75 Million SEK | -299.661% |
| Lipum AB (publ) | 37.3 Million SEK | -197.301% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -1429.005% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 18.393% |
| NextCell Pharma AB | -576.01 Thousand SEK | 19355.268% |
| OncoZenge AB (publ) | 15.9 Million SEK | -597.353% |
| Saniona AB (publ) | 1.07 Million SEK | -10198.422% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 38.969% |
| Ziccum AB (publ) | 27.87 Million SEK | -297.855% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -576.264% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 63.882% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -160.166% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -527.235% |
| Corline Biomedical AB | 30.16 Million SEK | -267.654% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | -91.129% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | -33.36% |
| Aptahem AB (publ) | 10.01 Million SEK | -1007.706% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 17.655% |
| Fluicell AB (publ) | 28.61 Million SEK | -287.581% |
| Biovica International AB (publ) | 133.72 Million SEK | 17.056% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -460.455% |
| AcouSort AB (publ) | 25.87 Million SEK | -328.637% |
| Abliva AB (publ) | 27.86 Million SEK | -298.026% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 42.68% |
| 2cureX AB (publ) | 36.51 Million SEK | -203.724% |
| I-Tech AB | 40.14 Million SEK | -176.263% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 87.095% |
| Cyxone AB (publ) | 28.21 Million SEK | -293.117% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | -1.414% |
| Biosergen AB | 26.8 Million SEK | -313.719% |
| Nanologica AB (publ) | 69.88 Million SEK | -58.705% |
| SynAct Pharma AB | 224.49 Million SEK | 50.594% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -151.073% |
| BioInvent International AB (publ) | 441.4 Million SEK | 74.872% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -363.024% |
| Alzinova AB (publ) | 36.39 Million SEK | -204.742% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 61.72% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -1311.79% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -654.517% |